← Leaderboards
Deborah Persaud
Johns Hopkins University
$30,632,571
Attributed
$49,982,996
Total exposure
26
Grants
20
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $7.3M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$49,982,996 · 26
By mechanism
UM1$30,092,882 · 1
R01$16,459,873 · 6
P01$1,598,378 · 1
R21$1,282,693 · 3
R56$468,656 · 1
M01$80,514 · 14
Top collaborators
- Yvonne J Bryson9 shared
- Ann M Chahroudi9 shared
- Katherine F Luzuriaga9 shared
Most similar at Johns Hopkins University
Same institution · by research overlap
- Laura A Guay$21,629,124
- Kenrad E Nelson$2,831,844
- Wells A Messersmith$5,466,310
- Mark A Riddle$6,095,923
- Taha E Taha$127,127,060
Others in their field
Top investigators on “Clinical Trials”
- Lawrence Corey · Fred Hutchinson Cancer Center$824,102,536
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$622,583,125
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$542,008,718
- Bambra Strokes · Ppd Development Lp$526,656,217
- Judith S. Currier · University Of California Los Angeles$504,273,077
Research focus
Clinical TrialsViralChildInfectionVirusAntiretroviral TherapyHiv-1InfantCellsChildhoodMemory Cd4 T LymphocyteLifeAdolescentRestDisease RemissionResponsePerinatal InfectionImmuneYoung AdultAdultSamplingInsightClinical ResearchCd4 Positive T Lymphocytes
Grant awards (67)
Pediatric Adolescent Virus Elimination (PAVE) Martin Delaney Collaboratory$5,433,689
UM1 · FY2025 · AI · contact PI
Impact of Neonatal ART and Broadly Neutralizing Antibodies on HIV-1 Reservoirs in Infants: Towards ART-free Remission$804,830
R01 · FY2025 · AI · contact PI
Virologic Determinants of Very Early Antiretroviral Treatment Responses of Infants with in utero HIV-1$232,500
R21 · FY2025 · HD · contact PI
Pediatric Adolescent Virus Elimination (PAVE) Martin Delaney Collaboratory$75,000
UM1 · FY2025 · AI · contact PI
Pediatric Adolescent Virus Elimination (PAVE) Martin Delaney Collaboratory$5,447,677
UM1 · FY2024 · AI · contact PI
Impact of Neonatal ART and Broadly Neutralizing Antibodies on HIV-1 Reservoirs in Infants: Towards ART-free Remission$877,580
R01 · FY2024 · AI · contact PI
Pediatric Adolescent Virus Elimination (PAVE) Martin Delaney Collaboratory$462,279
UM1 · FY2024 · AI · contact PI
Pediatric Adolescent Virus Elimination (PAVE) Martin Delaney Collaboratory$432,188
UM1 · FY2024 · AI · contact PI
Pediatric Adolescent Virus Elimination (PAVE) Martin Delaney Collaboratory$75,000
UM1 · FY2024 · AI · contact PI
Pediatric Adolescent Virus Elimination (PAVE) Martin Delaney Collaboratory$5,904,083
UM1 · FY2023 · AI · contact PI
Deciphering Mechanisms of HIV Latency Reversal in Perinatal Infections$750,353
R01 · FY2023 · AI · contact PI
Pediatric Adolescent Virus Elimination (PAVE) Martin Delaney Collaboratory$6,531,642
UM1 · FY2022 · AI · contact PI
Deciphering Mechanisms of HIV Latency Reversal in Perinatal Infections$752,530
R01 · FY2022 · AI · contact PI
Pediatric Adolescent Virus Elimination (PAVE) Martin Delaney Collaboratory$5,731,324
UM1 · FY2021 · AI · contact PI
Deciphering Mechanisms of HIV Latency Reversal in Perinatal Infections$769,890
R01 · FY2021 · AI · contact PI
Quantitative and Molecular Characterization of HIV Persistence and Rebound in Early and Very-Early ART Treated Children$283,129
P01 · FY2021 · AI · contact PI
Deciphering Mechanisms of HIV Latency Reversal in Perinatal Infections$807,906
R01 · FY2020 · AI · contact PI
Quantitative and Molecular Characterization of HIV Persistence and Rebound in Early and Very-Early ART Treated Children$302,444
P01 · FY2020 · AI · contact PI
Quantitative and Molecular Characterization of HIV Persistence and Rebound in Early and Very-Early ART Treated Children$323,779
P01 · FY2019 · AI · contact PI
Early Antiretroviral Therapy and HIV Remission in Perinatal Infection$1,162,650
R01 · FY2018 · HD · contact PI
Quantitative and Molecular Characterization of HIV Persistence and Rebound in Early and Very-Early ART Treated Children$333,422
P01 · FY2018 · AI · contact PI
Early Antiretroviral Therapy and HIV Remission in Perinatal Infection$1,167,223
R01 · FY2017 · HD · contact PI
Quantitative and Molecular Characterization of HIV Persistence and Rebound in Early and Very-Early ART Treated Children$355,604
P01 · FY2017 · AI · contact PI
Early Antiretroviral Therapy and HIV Remission in Perinatal Infection$69,945
R01 · FY2017 · HD · contact PI
Early Antiretroviral Therapy and HIV Remission in Perinatal Infection$1,160,228
R01 · FY2016 · HD · contact PI
Early Antiretroviral Therapy and HIV Remission in Perinatal Infection$221,705
R01 · FY2016 · HD · contact PI
Neutralization of the Latent HIV Reservoir in Perinatal Infection$202,500
R21 · FY2016 · HD · contact PI
Early Antiretroviral Therapy and HIV Remission in Perinatal Infection$81,324
R01 · FY2016 · HD · contact PI
Early Antiretroviral Therapy and HIV Remission in Perinatal Infection$1,172,270
R01 · FY2015 · HD · contact PI
Neutralization of the Latent HIV Reservoir in Perinatal Infection$243,000
R21 · FY2015 · HD · contact PI
Early Antiretroviral Therapy and HIV Remission in Perinatal Infection$153,714
R01 · FY2015 · HD · contact PI
Early Antiretroviral Therapy and HIV Remission in Perinatal Infection$1,266,917
R01 · FY2014 · HD · contact PI
Markers of Long-Term Suppression of HIV in Pre-adolescents treated from Infancy$321,193
R21 · FY2014 · AI · contact PI
Markers of Long-Term Suppression of HIV in Pre-adolescents treated from Infancy$283,500
R21 · FY2013 · AI · contact PI
HIV Integration Profiling and Viral Persistence in Children and Youth$468,656
R56 · FY2011 · AI · contact PI
HIV-1 chemoprophylaxis and archived drug resistance in infants$394,595
R01 · FY2010 · HD · contact PI
HIV-1 chemoprophylaxis and archived drug resistance in infants$655,545
R01 · FY2009 · HD · contact PI
HIV-1 chemoprophylaxis and archived drug resistance in infants$637,517
R01 · FY2008 · HD · contact PI
HIV Vaccines on Latent Reservoirs in Young Adults on HAART$390,546
R01 · FY2008 · AI · contact PI
HIV-1 chemoprophylaxis and archived drug resistance in infants$599,746
R01 · FY2007 · HD · contact PI
HIV Drug Resistance During HAART in Adolescents$421,968
R01 · FY2007 · AI · contact PI
HIV Vaccines on Latent Reservoirs in Young Adults on HAART$398,110
R01 · FY2007 · AI · contact PI
PACTG P1038$7,986
M01 · FY2007 · RR · contact PI
P1034 10$615
M01 · FY2007 · RR · contact PI
PACTG P1030$614
M01 · FY2007 · RR · contact PI
HIV Drug Resistance During HAART in Adolescents$432,284
R01 · FY2006 · AI · contact PI
HIV Vaccines on Latent Reservoirs in Young Adults on HAART$402,400
R01 · FY2006 · AI · contact PI
PACTG P1030$13,182
M01 · FY2006 · RR · contact PI
PHARMACOKINETIC STUDY OF LOPINAVIR/RITONAVIR$6,328
M01 · FY2006 · RR · contact PI
P1034 10$3,164
M01 · FY2006 · RR · contact PI
PACTG: P1006$1,055
M01 · FY2006 · RR · contact PI
PACTG 356$527
M01 · FY2006 · RR · contact PI
HIV Drug Resistance During HAART in Adolescents$362,634
R01 · FY2005 · AI
PACTG P1020A$18,598
M01 · FY2005 · RR
PACTG P1030$11,443
M01 · FY2005 · RR
PACTG: P1006$6,437
M01 · FY2005 · RR
PACTG 356$3,577
M01 · FY2005 · RR
HIV Drug Resistance During HAART in Adolescents$367,875
R01 · FY2004 · AI
PACTG P1030$3,289
M01 · FY2004 · RR
PACTG P1020A$1,233
M01 · FY2004 · RR
PACTG: P1006$1,233
M01 · FY2004 · RR
PACTG 356$822
M01 · FY2004 · RR
PACTG P1015$411
M01 · FY2004 · RR
HIV Drug Resistance During HAART in Adolescents$177,588
R01 · FY2003 · AI
ACTG 230--HIV 1 ENVELOPE ANTIGEN IN INFANT OF HIV MOTHER$0
M01 · FY2002 · RR
ACTG 230--HIV 1 ENVELOPE ANTIGEN IN INFANT OF HIV MOTHER$0
M01 · FY2001 · RR
ACTG 230--HIV 1 ENVELOPE ANTIGEN IN INFANT OF HIV MOTHER$0
M01 · FY2000 · RR